Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis

BACKGROUND AND AIM: It is unclear how adding an anti‐tumor necrosis factor alpha agent to immunomodulator (IM) treatment, as a step‐up strategy, affects long‐term outcomes in ulcerative colitis. This retrospective study investigated persistence associated with biologic anti‐tumor necrosis factor alp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Taku, Udagawa, Eri, Uda, Akihito, Hibi, Toshifumi, Hisamatsu, Tadakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027773/
https://www.ncbi.nlm.nih.gov/pubmed/31397010
http://dx.doi.org/10.1111/jgh.14825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027773/
https://www.ncbi.nlm.nih.gov/pubmed/31397010
http://dx.doi.org/10.1111/jgh.14825

Ejemplares similares